SARA REISCHMAN: Open Payments
NPI 1861086803 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,017 in 230 payments from 23 companies in 2025. Trend: 2023 $1,720 · 2024 $3,813 · 2025 $6,017
Food & beverage: $6,017
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 52 | $1,130 |
| NeurAxis, Inc. | 1 | $940 |
| Janssen Biotech, Inc. | 31 | $703 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $542 |
| Madrigal Pharmaceuticals | 8 | $463 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $407 |
| Lilly USA, LLC | 14 | $294 |
| Regeneron Healthcare Solutions, Inc. | 10 | $268 |
| Ardelyx, Inc. | 13 | $259 |
| GENZYME CORPORATION | 4 | $176 |
Products named: TREMFYA, RINVOQ, ENTYVIO, REZDIFFRA, DUPIXENT, XIFAXAN, OMVOH, IBSRELA.
Industry payments across IN — which companies pay providers there.
